Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Podoplanin expression in oral leukoplakia: tumorigenic role.

de Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-Fernández P, Allonca E, García-Pedrero JM.

Oral Oncol. 2013 Jun;49(6):598-603. doi: 10.1016/j.oraloncology.2013.02.008. Epub 2013 Mar 7.

PMID:
23473850
2.

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L.

J Clin Oncol. 2008 Jan 20;26(3):354-60. doi: 10.1200/JCO.2007.13.4072.

PMID:
18202409
3.

Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications.

Kreppel M, Kreppel B, Drebber U, Wedemayer I, Rothamel D, Zöller JE, Scheer M.

Oral Dis. 2012 Oct;18(7):692-9. doi: 10.1111/j.1601-0825.2012.01927.x. Epub 2012 Apr 4.

PMID:
22471854
4.

[Podoplanin expression in oral squamous cell carcinoma and leukoplakia and its correlation with lymph vessels density].

Zhang G, Guo ZL, Gao Y.

Zhonghua Kou Qiang Yi Xue Za Zhi. 2009 Aug;44(8):488-91. Chinese.

PMID:
19961757
5.

Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.

Schaaij-Visser TB, Bremmer JF, Braakhuis BJ, Heck AJ, Slijper M, van der Waal I, Brakenhoff RH.

Oral Oncol. 2010 Feb;46(2):123-7. doi: 10.1016/j.oraloncology.2009.11.012. Epub 2009 Dec 29.

PMID:
20036603
6.

Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland.

Cruz I, Napier SS, van der Waal I, Snijders PJ, Walboomers JM, Lamey PJ, Cowan CG, Gregg TA, Maxwell P, Meijer CJ.

J Clin Pathol. 2002 Feb;55(2):98-104.

7.

E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: a retrospective cohort study.

von Zeidler SV, de Souza Botelho T, Mendonça EF, Batista AC.

BMC Cancer. 2014 Dec 17;14:972. doi: 10.1186/1471-2407-14-972.

8.

Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.

Soni S, Kaur J, Kumar A, Chakravarti N, Mathur M, Bahadur S, Shukla NK, Deo SV, Ralhan R.

Oncology. 2005;68(4-6):314-25. Epub 2005 Jul 12.

PMID:
16020958
9.

Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia.

Kurokawa H, Matsumoto S, Murata T, Yamashita Y, Tomoyose T, Zhang M, Fukuyama H, Takahashi T.

J Oral Pathol Med. 2003 Oct;32(9):513-21.

PMID:
12969225
10.

Expression of podoplanin in oral premalignant and malignant lesions and its potential as a biomarker.

Logeswari J, Malathi N, Thamizhchelvan H, Sangeetha N, Nirmala SV.

Indian J Dent Res. 2014 May-Jun;25(3):305-10. doi: 10.4103/0970-9290.138321.

11.

p53 immunoprofiling of potentially malignant oral disorders: a case series analysis.

Reddy VM, Kamath A, Radhakrishnan RA.

Indian J Cancer. 2012 Jan-Mar;49(1):27-32. doi: 10.4103/0019-509X.98913.

12.

Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance.

dos Santos Almeida A, Oliveira DT, Pereira MC, Faustino SE, Nonogaki S, Carvalho AL, Kowalski LP.

Anticancer Res. 2013 Sep;33(9):3969-76.

PMID:
24023336
13.

p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma.

Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM, van der Waal I.

J Pathol. 1998 Apr;184(4):360-8.

PMID:
9664901
14.

DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.

Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L.

Clin Cancer Res. 2009 Oct 1;15(19):6284-91. doi: 10.1158/1078-0432.CCR-09-0498. Epub 2009 Sep 22.

15.

Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.

Seki S, Fujiwara M, Matsuura M, Fujita S, Ikeda H, Umeda M, Asahina I, Ikeda T.

Pathol Oncol Res. 2014 Jul;20(3):521-8. doi: 10.1007/s12253-013-9723-0. Epub 2013 Nov 28.

PMID:
24281769
16.

The combination of SMAD4 expression and histological grade of dysplasia is a better predictor for the malignant transformation of oral leukoplakia.

Xia RH, Song XM, Wang XJ, Li J, Mao L.

PLoS One. 2013 Jun 24;8(6):e66794. doi: 10.1371/journal.pone.0066794. Print 2013.

17.

Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas.

Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M, Kundu S, Shingaki S, Saito C, Saku T.

Pathobiology. 2011;78(3):171-80. doi: 10.1159/000324926. Epub 2011 May 26.

PMID:
21613804
18.

Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.

Ries J, Agaimy A, Vairaktaris E, Kwon Y, Neukam FW, Strassburg LH, Nkenke E.

Int J Oncol. 2012 Sep;41(3):1085-93. doi: 10.3892/ijo.2012.1532. Epub 2012 Jun 26.

PMID:
22751922
19.

Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.

Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L.

Cancer. 2006 Aug 1;107(3):563-9.

20.

The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia.

Ries J, Vairaktaris E, Agaimy A, Bechtold M, Gorecki P, Neukam FW, Nkenke E.

Oncol Rep. 2013 Sep;30(3):1149-56. doi: 10.3892/or.2013.2545. Epub 2013 Jun 19.

PMID:
23784518

Supplemental Content

Support Center